RecruitingNCT06830759
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
Studying Epstein-Barr virus-positive diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AbbVie
- Principal Investigator
- ABBVIE INC.AbbVie
- Enrollment
- 700 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2031
Study locations (30)
- Hospital Britanico de Buenos Aires /ID# 274419, Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
- Hospital Universitario Austral /ID# 274393, Pilar, Buenos Aires, Argentina
- Instituto Alexander Fleming /ID# 277284, Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina
- Hospital Privado Universitario De Córdoba /ID# 274457, Córdoba, Córdoba Province, Argentina
- Hospital Italiano de Buenos Aires /ID# 274418, Buenos Aires, Argentina
- Fundacion Argentina contra la Leucemia (FUNDALEU) /ID# 274390, Buenos Aires, Argentina
- Nepean Cancer Centre, Nepean Hospital /ID# 277782, Kingswood, New South Wales, Australia
- Calvary Mater Newcastle /ID# 277783, Waratah, New South Wales, Australia
- Cabrini Hospital Malvern /ID# 277780, Malvern, Victoria, Australia
- Krankenhaus Der Barmherzigen Brueder Graz /ID# 273288, Graz, Styria, Austria
- Landeskrankenhaus Hochsteiermark, Standort Leoben /ID# 273266, Leoben, Styria, Austria
- Algemeen Ziekenhuis klina /ID# 273405, Brasschaat, Antwerpen, Belgium
- Universitair Ziekenhuis Brussel /ID# 273403, Jette, Brussels Capital, Belgium
- Centre Hospitalier Epicura - Hornu /ID# 273406, Boussu, Hainaut, Belgium
- Grand Hôpital De Charleroi - Notre Dame /ID# 273728, Charleroi, Hainaut, Belgium
- +15 more locations on ClinicalTrials.gov
Collaborators
Genmab
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06830759 on ClinicalTrials.govOther trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07162012Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive LymphomaShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGPHASE2NCT06846463Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+Virginia Commonwealth University
- RECRUITINGNCT06588205Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell LymphomaFondazione Italiana Linfomi - ETS
- RECRUITINGPHASE3NCT06929624A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell LymphomaSuzhou Suncadia Biopharmaceuticals Co., Ltd.
- RECRUITINGPHASE1NCT06830031Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell LymphomaShanghai Exuma Biotechnology Ltd.
- RECRUITINGNCT07198230Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell LymphomaTing YANG
- RECRUITINGPHASE2NCT07254754Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell LymphomaGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- RECRUITINGPHASE3NCT06522555The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaRuijin Hospital
See all trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma →